NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

學名藥的全球市場

Generic Drugs

出版商 Global Industry Analysts, Inc. 商品編碼 997464
出版日期 內容資訊 英文 285 Pages
商品交期: 最快1-2個工作天內
價格
學名藥的全球市場 Generic Drugs
出版日期: 2021年05月01日內容資訊: 英文 285 Pages
簡介

全球學名藥的市場規模,預計在分析期間(2020年∼2027年)將以9.4%的年複合成長率增長,從2020年的2,860億美元,到2027年達到5,355億美元。

本報告所分析的市場區隔之一的純仿製藥部門,在分析期間中預計將以9.1%的年複合成長率增長,達到3,532億美元。

本報告提供全球學名藥市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Fresenius Kabi AG
  • Mylan Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:42公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP12162

Abstract:

Global Generic Drugs Market to Reach US$536.4 Billion by the Year 2027

Amid the COVID-19 crisis, the global market for Generic Drugs estimated at US$365.9 Billion in the year 2020, is projected to reach a revised size of US$536.4 Billion by 2027, growing at a CAGR of 5.6% over the period 2020-2027.Small-Molecule Generics, one of the segments analyzed in the report, is projected to grow at a 5.2% CAGR to reach US$325.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biosimilars segment is readjusted to a revised 6.3% CAGR for the next 7-year period. This segment currently accounts for a 37.7% share of the global Generic Drugs market.

The U.S. Accounts for Over 30.5% of Global Market Size in 2020, While China is Forecast to Grow at a 7.2% CAGR for the Period of 2020-2027

The Generic Drugs market in the U.S. is estimated at US$111.4 Billion in the year 2020. The country currently accounts for a 30.46% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$97.6 Billion in the year 2027 trailing a CAGR of 7.2% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR while Rest of European market (as defined in the study) will reach US$97.6 Billion by the year 2027.

Select Competitors (Total 42 Featured) -

  • Fresenius Kabi AG
  • Mylan Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Impact of Covid-19 and a Looming Global Recession
    • The Race Between the Virus & Vaccines Intensifies. Amidst this Chaotic Battle, Where is the World Economy Headed in 2021?
    • EXHIBIT 1: How Fast the World is Vaccinated Will Determine How Soon the Pandemic Will End: Global Number of Annual COVID-19 Vaccine Doses (In Million) for Years 2020 through 2025 by Geographic Region/Country
    • Progress on Vaccinations, Why Should Businesses Care?
    • These are Times When Questions Abound & Answers Are Few
    • With IMF's Upward Revision of Global GDP Forecasts for 2021, Most Companies Are Bullish About a Global Economic Comeback.
    • EXHIBIT 2: A Strong 2021 Economic Rebound Based On Pent-Up Demand Comes as a Relief for Suffering Industries & Markets: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
    • How the Healthcare Industry Has & Continues to be Impacted by the Pandemic & What's the New Normal?
    • EXHIBIT 3: With the COVID-19 Pandemic Exposing Global Healthcare Unpreparedness, There is Increasing Policy Led Focus on Rebooting Health Systems Worldwide: Current & Required Healthcare Spending as % of GDP
    • Impact of COVID-19 Crisis on Generic Drugs Market
    • Demand for Generic Pain Killers Rises
    • A Prelude to Generic Drugs
    • Generic Drugs Market Set for a Rapid Growth
    • US Dominates, Asia-Pacific to Exhibit the Fastest Growth
    • India- A Significant Market
    • Market Restraints
    • Competition
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Patent Expiries Set to Widen the Addressable Market for Generic Drugs
    • EXHIBIT 4: Patent Expiries of Select Drugs in 2020
    • EXHIBIT 5: Patent Expiries of Select Drugs in 2021
    • EXHIBIT 6: Patent Expiries of Select Drugs in 2022
    • Patent Expiry of Select Major Drugs in the US: 2020-2022
    • Robust Demand for Pharmaceutical Drugs Drives Demand for Generic Drugs
    • Cost Containment Measures Put Focus on Generics
    • Small Molecule Generics Represent the Dominant Segment
    • Increasing Demand for Biosimilars, Driven by Patent Expiry of Major Biopharmaceutical Drugs
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
    • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
    • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
    • Biosimilars Regulatory Agencies in Select Regional Markets
    • Biosimilar Approvals in the US (as of February 2021)
    • Biosimilar Approvals in Europe (as of January 2021)
    • Rising Healthcare Costs Drive Demand for Generic Drugs
    • EXHIBIT 7: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Aging Population to Propel the Demand for Generic Drugs
    • EXHIBIT 8: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Rising Prevalence of Chronic Diseases Drive the Demand for Generic Drugs
    • EXHIBIT 9: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • EXHIBIT 10: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    • EXHIBIT 11: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • EXHIBIT 12: Number of New Cancer Cases and Deaths (in Million) by Region for 2018
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Generic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Small-Molecule Generics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Small-Molecule Generics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Central Nervous System (CNS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Central Nervous System (CNS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Dermatology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Dermatology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Other Therapeutic Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Other Therapeutic Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 28: USA Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: USA Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: USA 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 34: Canada Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: Canada Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Canada 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 40: Japan Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Japan Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Japan 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 43: Japan Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 46: China Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: China Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: China 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 49: China Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: China 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 52: Europe Current & Future Analysis for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 53: Europe Historic Review for Generic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Europe 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 55: Europe Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 58: Europe Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 61: France Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: France Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: France 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 64: France Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: France Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: France 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 67: Germany Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Germany Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Germany 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 70: Germany Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Germany Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Germany 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 73: Italy Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Italy Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Italy 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 76: Italy Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Italy Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Italy 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 79: UK Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: UK Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: UK 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 82: UK Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: UK Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: UK 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 85: Spain Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Spain Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Spain 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 88: Spain Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Spain Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Spain 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 91: Russia Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Russia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Russia 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 94: Russia Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Russia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Russia 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 97: Rest of Europe Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Rest of Europe Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Rest of Europe 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 100: Rest of Europe Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of Europe Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of Europe 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 103: Asia-Pacific Current & Future Analysis for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 104: Asia-Pacific Historic Review for Generic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Asia-Pacific 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 106: Asia-Pacific Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Asia-Pacific 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 109: Asia-Pacific Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Asia-Pacific 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 112: Australia Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: Australia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: Australia 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 115: Australia Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Australia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Australia 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 118: India Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: India Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: India 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 121: India Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: India Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 123: India 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 124: South Korea Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 125: South Korea Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 126: South Korea 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 127: South Korea Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: South Korea Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 129: South Korea 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 130: Rest of Asia-Pacific Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 131: Rest of Asia-Pacific Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 132: Rest of Asia-Pacific 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 133: Rest of Asia-Pacific Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Rest of Asia-Pacific Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 135: Rest of Asia-Pacific 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 136: Latin America Current & Future Analysis for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 137: Latin America Historic Review for Generic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 138: Latin America 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 139: Latin America Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 141: Latin America 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 142: Latin America Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 143: Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 144: Latin America 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 145: Argentina Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 146: Argentina Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 147: Argentina 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 148: Argentina Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 149: Argentina Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 150: Argentina 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 151: Brazil Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 152: Brazil Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 153: Brazil 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 154: Brazil Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 155: Brazil Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 156: Brazil 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 157: Mexico Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 158: Mexico Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 159: Mexico 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 160: Mexico Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 161: Mexico Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 162: Mexico 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 163: Rest of Latin America Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Latin America Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 165: Rest of Latin America 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 166: Rest of Latin America Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 167: Rest of Latin America Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 168: Rest of Latin America 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 169: Middle East Current & Future Analysis for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 170: Middle East Historic Review for Generic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 171: Middle East 15-Year Perspective for Generic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 172: Middle East Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 173: Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 174: Middle East 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 175: Middle East Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 177: Middle East 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 178: Iran Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 179: Iran Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 180: Iran 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 181: Iran Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Iran Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 183: Iran 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 184: Israel Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 185: Israel Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 186: Israel 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 187: Israel Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Israel Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 189: Israel 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 190: Saudi Arabia Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 191: Saudi Arabia Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 192: Saudi Arabia 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 193: Saudi Arabia Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Saudi Arabia Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 195: Saudi Arabia 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 196: UAE Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 197: UAE Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 198: UAE 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 199: UAE Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 200: UAE Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 201: UAE 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 202: Rest of Middle East Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 203: Rest of Middle East Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 204: Rest of Middle East 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 205: Rest of Middle East Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Rest of Middle East Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 207: Rest of Middle East 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 208: Africa Current & Future Analysis for Generic Drugs by Type - Small-Molecule Generics and Biosimilars - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 209: Africa Historic Review for Generic Drugs by Type - Small-Molecule Generics and Biosimilars Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 210: Africa 15-Year Perspective for Generic Drugs by Type - Percentage Breakdown of Value Sales for Small-Molecule Generics and Biosimilars for the Years 2012, 2020 & 2027
    • TABLE 211: Africa Current & Future Analysis for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Africa Historic Review for Generic Drugs by Therapeutic Application - Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 213: Africa 15-Year Perspective for Generic Drugs by Therapeutic Application - Percentage Breakdown of Value Sales for Cardiovascular, Central Nervous System (CNS), Dermatology, Oncology, Respiratory and Other Therapeutic Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 248